Welcome to our dedicated page for Envoy Medical news (Ticker: COCH), a resource for investors and traders seeking the latest updates and insights on Envoy Medical stock.
Envoy Medical, Inc. develops hearing-health technologies focused on fully implanted hearing solutions. The company’s portfolio includes the Esteem FI-AMEI, an FDA-approved fully implanted active middle ear implant for adults with moderate to severe sensorineural hearing loss, and the investigational Acclaim cochlear implant, which uses a sensor designed to work with the ear’s natural anatomy rather than an external microphone.
Recurring company news covers Acclaim clinical-study updates, FDA-related development toward a Premarket Approval pathway, financial results, capital-structure actions, Nasdaq listing compliance, board and governance changes, and intellectual-property updates tied to its hearing segment.
Envoy Medical (NASDAQ: COCH), a hearing health company, has closed its previously announced registered direct offering, raising $2.5 million through the sale of 1,908,402 shares of Class A common stock at $1.31 per share.
The company also conducted a concurrent private placement of unregistered warrants to purchase up to 5,725,206 shares at an exercise price of $1.31 per share. If fully exercised, these warrants could provide additional gross proceeds of $7.5 million. The warrants will be exercisable after stockholder approval and expire 24 months thereafter.
H.C. Wainwright & Co. served as the exclusive placement agent, and Envoy Medical plans to use the net proceeds for working capital and general corporate purposes.
Envoy Medical (NASDAQ: COCH) is advancing commercialization plans for its breakthrough Acclaim® fully implanted cochlear implant while its FDA pivotal trial progresses successfully. The trial has reached significant milestones with all patients completing three-month follow-ups with no serious adverse events, and six-month follow-ups now underway.
The company plans to establish 30-40 clinical sites upon FDA approval, focusing on excellence and strong foundation building. The Acclaim device, which received FDA Breakthrough Device Designation in 2019, is targeting PMA submission in 2027. Envoy Medical aims to tap into an underserved market segment of individuals who haven't adopted traditional hearing loss treatments.
Envoy Medical (NASDAQ: COCH), a hearing health company, has announced a $2.5 million registered direct offering priced at-the-market under Nasdaq rules. The company will issue 1,908,402 shares of Class A common stock at $1.31 per share.
Additionally, in a concurrent private placement, Envoy will issue unregistered warrants to purchase up to 5,725,206 shares at an exercise price of $1.31 per share. If these warrants are fully exercised, the company could receive additional gross proceeds of approximately $7.5 million. H.C. Wainwright & Co. is serving as the exclusive placement agent, with the offering expected to close around September 23, 2025.
Envoy Medical (NASDAQ: COCH) has been granted European Patent No. 4338791 for its innovative cochlear implant technology, effective September 17, 2025. The patent specifically covers systems and methods for compensating for variability in middle ear sensors using analog and digital signals.
This patent adds to Envoy Medical's recent patent acquisitions in the United States, Australia, and Hong Kong. The technology relates to their investigational Acclaim® Cochlear Implant, which uniquely eliminates external microphones and hardware by leveraging the natural ear, potentially transforming treatment for severe to profound sensorineural hearing loss.
Envoy Medical (NASDAQ: COCH), a hearing health company, has announced significant achievements in Q3 2025. The company has completely eliminated over $32 million in debt, strengthening its balance sheet and capital structure. Envoy has expanded its global patent portfolio with 7 new patents across the U.S., Australia, and Hong Kong, now holding approximately 38 U.S. and 40 foreign patents.
The company reported positive progress in its pivotal clinical trial for the Acclaim® fully implanted cochlear implant, with all 10 initial patients completing three-month follow-ups without serious adverse events. Additionally, five new Category III CPT codes for totally-implantable active middle ear implants, including their FDA-approved Esteem® device, took effect on July 1, 2025, potentially improving reimbursement opportunities.
Envoy Medical (NASDAQ: COCH) has secured four new global patents, strengthening its position in fully implantable hearing technology. The patents include three Australian patents and one U.S. patent, focusing on programming cochlear implant accessories, lead characterization, and integrated signal analysis functionality.
These patents enhance Envoy Medical's ability to develop and protect innovations for next-generation cochlear implant solutions that offer patients a discreet, 24/7 hearing experience without external components. CEO Brent Lucas emphasized that these patents represent a crucial step in strengthening their global intellectual property portfolio and advancing their mission to deliver transformative hearing solutions.
Envoy Medical (NASDAQ: COCH), a hearing health company specializing in fully implanted hearing solutions, announced that CEO Brent Lucas will deliver a virtual presentation at the H.C. Wainwright 27th Annual Global Investment Conference taking place from September 8-10, 2025, in New York City.
The presentation is available on-demand through the company's investor relations website and can be accessed via a direct link. Interested parties can join Envoy Medical's email distribution list by contacting Envoy@kcsa.com with COCH in the subject line.
Envoy Medical (NASDAQ: COCH) has announced a significant milestone in its pivotal clinical trial for the Acclaim® fully implanted cochlear implant. The first stage patients have successfully reached their three-month follow-up with no serious adverse events (SAEs) or unanticipated device effects (UADEs) reported.
The Acclaim® device, designed to be the first-of-its-kind fully implanted cochlear implant, features Invisible Hearing® technology with no external components, natural ear sound capture, in-ear flexibility for consumer electronics use, extended battery life, and wireless update capabilities. The company remains on track for FDA approval submission in 2027.
Envoy Medical (NASDAQ: COCH), a hearing health company focused on fully implanted hearing solutions, has announced the extinguishment of $32 million in debt from GAT Funding, LLC for a payment of just $100,000 in cash. The company also announced the retirement of Glen A. Taylor from its board after nearly two decades of service.
This strategic financial move eliminates all term loan obligations without equity conversion, significantly strengthening the company's balance sheet. The debt extinguishment allows Envoy Medical to focus its capital resources on developing its lead product candidate, the investigational Acclaim® cochlear implant.
Envoy Medical (NASDAQ: COCH), a hearing health company, has secured three significant patents across the United States, Australia, and Hong Kong for its fully implantable hearing technology. The patents include U.S. Patent No. 12,390,634 for a modular cochlear implant system, Australian Patent No. 2022254630 for electrode impedance diagnostics, and Hong Kong Patent No. 40101898 for cochlear implant stimulation calibration.
These patents strengthen Envoy Medical's intellectual property portfolio in developing next-generation cochlear implant solutions that provide patients with a discreet, 24/7 hearing experience without external components. The technology focuses on innovative features such as implantable batteries, communication modules, and improved electrode diagnostics.